FDA extends safety review of abortion pill mifepristone into 2027

The FDA announced its safety review of mifepristone, the primary abortion pill, will extend into next year, delaying a final regulatory decision. Abortion opponents condemned the timeline, while supporters see it as a cautious approach. The delay prolongs regulatory uncertainty for abortion access in the U.S.